MAP2K7 and neoplasm: A phase I/II study, (NCT03947385) designed to characterise the safety and anti-tumour action of darovasertib in patients with solid tumours harbouring GNAQ/11 mutations, including MUM, CMM, and colorectal cancer among others, with an approximate completion date of late 2022–2023, presented in July 2021 a preliminary robust 57% 1-year OS in monotherapy and early partial responses, in combination with binimetinib (MEK inhibitor) and crizotinib (c-MET inhibitor), in the group of patients with MUM.